adenocarcinoma;
needle biopsy;
prostate specific antigen;
prostate;
prostatectomy;
staging;
D O I:
10.1111/j.1442-2042.2007.01795.x
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
1002 ;
100201 ;
摘要:
Objective: To identify the most reliable predictor of the pathological stage among multiple parameters obtained by performing systematic biopsies and to assess the predictive value of any identified parameters in combination with the prostate specific antigen and the Gleason scores. Methods: We examined 5 biopsy parameters from 12 systematic needle biopsy results in 104 consecutive prostate cancer patients who underwent prostatectomy: the number of cores positive for cancer, percentage of positive biopsy cores, total linear cancer length (absolute sum of tumor length at each core), percentage cancer length (total cancer length divided by total length of cores obtained x100), and maximum cancer core length. The predictive values of these parameters were assessed using multivariate logistic analysis and receiver operating characteristic analysis. We evaluated whether the most reliable biopsy parameter in combination with traditional variables show better predictability of the pathological stage than traditional variables alone by receiver operating characteristic analysis. Results: Of 104 patients, 85 (82.9%) had organ confined cancer and 19 (17.1%) showed extraprostatic extension. Of the five parameters examined, maximum cancer length was found to best predict pathological staging. Although insignificant, adding results of maximum cancer length to prostate specific antigen and Gleason scores improved predictability. Of 41 patients with a maximum cancer length of < 0.9 cm, PSA of < 16 ng/mL, and Gleason score of < 7, none showed extraprostatic extension. Conclusions: The maximum cancer length was found to be the most reliable predictor of disease staging. The findings of a maximum cancer length of < 0.9 cm, PSA of < 16 ng/mL, and a Gleason score of < 7 can suggest an organ-confined disease.
机构:
Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USAMem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
Fine, Samson W.
Amin, Mahul B.
论文数: 0引用数: 0
h-index: 0
机构:
Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USAMem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
Amin, Mahul B.
Berney, Daniel M.
论文数: 0引用数: 0
h-index: 0
机构:
Queen Mary Univ London, St Bartholomews Hosp, Dept Mol Oncol & Imaging, London, EnglandMem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
Berney, Daniel M.
Bjartell, Anders
论文数: 0引用数: 0
h-index: 0
机构:
Skane Univ Hosp, Dept Urol, Malmo, SwedenMem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
Bjartell, Anders
Egevad, Lars
论文数: 0引用数: 0
h-index: 0
机构:
Karolinska Inst, Dept Oncol Pathol, Stockholm, SwedenMem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
Egevad, Lars
Epstein, Jonathan I.
论文数: 0引用数: 0
h-index: 0
机构:
Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD 21287 USA
Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA
Johns Hopkins Univ Hosp, Dept Urol, Baltimore, MD 21287 USAMem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
Epstein, Jonathan I.
Humphrey, Peter A.
论文数: 0引用数: 0
h-index: 0
机构:
Washington Univ, Dept Pathol & Immunol, Sch Med, St Louis, MO USAMem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
Humphrey, Peter A.
Magi-Galluzzi, Christina
论文数: 0引用数: 0
h-index: 0
机构:
Cleveland Clin, Dept Anat Pathol, Cleveland, OH 44106 USA
Case Western Reserve Univ, Lerner Coll Med, Cleveland, OH 44106 USAMem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
Magi-Galluzzi, Christina
Montironi, Rodolfo
论文数: 0引用数: 0
h-index: 0
机构:
Polytech Univ Marche Reg, United Hosp, Sch Med, Sect Pathol Anat, Ancona, ItalyMem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA
Montironi, Rodolfo
Stief, Christian
论文数: 0引用数: 0
h-index: 0
机构:
Univ Munich, Dept Urol, Munich, GermanyMem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA